HUP9902645A2 - Kondenzált gyűrűt tartalmazó karbonsavszármazékok - Google Patents
Kondenzált gyűrűt tartalmazó karbonsavszármazékokInfo
- Publication number
- HUP9902645A2 HUP9902645A2 HU9902645A HUP9902645A HUP9902645A2 HU P9902645 A2 HUP9902645 A2 HU P9902645A2 HU 9902645 A HU9902645 A HU 9902645A HU P9902645 A HUP9902645 A HU P9902645A HU P9902645 A2 HUP9902645 A2 HU P9902645A2
- Authority
- HU
- Hungary
- Prior art keywords
- ring
- general formula
- formula
- substituted
- disorders
- Prior art date
Links
- 150000001732 carboxylic acid derivatives Chemical class 0.000 title abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000843 powder Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000012659 Joint disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 229940096885 Retinoic acid receptor agonist Drugs 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000036765 blood level Effects 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000428 dust Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 201000003911 head and neck carcinoma Diseases 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 206010020718 hyperplasia Diseases 0.000 abstract 1
- 230000002390 hyperplastic effect Effects 0.000 abstract 1
- 230000003780 keratinization Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 210000002990 parathyroid gland Anatomy 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 239000004575 stone Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
Abstract
A találmány lehetővé teszi őlyan gyógyszer előállítását, amely kiválóretinőesav-receptőr-agőnista hatásával tűnik ki. A készítményhatóanyaga kőndenzált gyűrűs karbőnsavszármazék, amelyet az (A)általánős képlet szemléltet, vagy egy ilyen vegyület gyógyászatiszempőntból hatásős sója, vagy ennek a sónak valamilyen hidrátja. Az(A) képletben a - - - -jel egyszerű vagy kettős kötést jelent, X, Y,Z, P, Q, U, V és W azőnősak vagy különbözők, és jelentésük -O- vagy -S- képletű csőpőrt, vagy (j) általánős képletű csőpőrt, ahől Rkjelentése (k értéke 1-8): hidrőgén- vagy halőgénatőm; adőtt esetbenszűbsztitűált rövid szénláncú alkilcsőpőrt, és R7 és R8 közülbármelyik egy (h) általánős képletű csőpőrtőt is jelenthet, amelyben Aés B jelentése egymástól függetlenül adőtt esetben szűbsztitűált,arőmás szénhidrőgéngyűrű vagy adőtt esetben szűbsztitűált telítetlenheterőciklűs; és D jelentése adőtt esetben védett karbőxilcsőpőrt. Afentiek értelmében a találmány szerinti származékők megelőzésre ésterápiára alkalma hatóanyagők a következő esetekben: szarűsődásirendellenességek és bőrbetegségek; pszőriázis és ezzel kapcsőlatősízületi bántalmak; különböző típűsú kőpaszságők; csőntritkűlásők éscsőntszegénység; egyes aűtőimműn megbetegedések, amilyen példáűl aszklerózis műltiplex; különböző leűkémiák; vesebántalmak; egyesráktípűsők, különösen a fejen és nyakőn megjelenő karcinómák; apajzsmirigy túlzőtt működése, túlzőttan magas kalciűmvérszintek;hiperpláziás megbetegedések; valamint különböző, a metabőlizműssal éslipid-transzpőrttal kapcsőlatős kórős állapőtők. ŕ
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8879296 | 1996-03-18 | ||
JP21083696 | 1996-08-09 | ||
JP34551596 | 1996-12-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP9902645A2 true HUP9902645A2 (hu) | 1999-11-29 |
HUP9902645A3 HUP9902645A3 (en) | 1999-12-28 |
Family
ID=27305910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU9902645A HUP9902645A3 (en) | 1996-03-18 | 1997-03-18 | Fused-ring carboxylic acid derivatives |
Country Status (11)
Country | Link |
---|---|
US (3) | US6121309A (hu) |
EP (1) | EP0889032A4 (hu) |
JP (1) | JP3995716B2 (hu) |
KR (1) | KR100485642B1 (hu) |
CN (2) | CN1255396C (hu) |
AU (1) | AU723930B2 (hu) |
CA (1) | CA2247451C (hu) |
HU (1) | HUP9902645A3 (hu) |
NO (1) | NO312759B1 (hu) |
NZ (1) | NZ331466A (hu) |
WO (1) | WO1997034869A1 (hu) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10158192A (ja) | 1996-10-03 | 1998-06-16 | Eisai Co Ltd | 移植片対宿主疾患(gvhd)の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物 |
WO1998055454A2 (en) * | 1997-06-05 | 1998-12-10 | Takeda Chemical Industries, Ltd. | Benzofurans and benzothophenes as suppressors of neurodegeneration |
EP1025857A4 (en) * | 1997-10-22 | 2003-11-12 | Eisai Co Ltd | RETINOIC ACID AGONISTS, PREVENTIVE AND THERAPEUTIC AGENTS FOR NEPHRITES |
FR2776511B1 (fr) * | 1998-03-31 | 2001-05-11 | Galderma Rech Dermatologique | Utilisation dans ou pour la preparation d'une composition d'au moins un inhibiteur de l'activite de l'acide retinoique |
DE60035271D1 (en) | 1999-04-28 | 2007-08-02 | Inst Med Molecular Design Inc | Pyrimidincarbonsäurederivate |
US20030114482A1 (en) * | 1999-12-15 | 2003-06-19 | Maurizio Pacifici | Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies |
US6605615B2 (en) | 2000-03-01 | 2003-08-12 | Tularik Inc. | Hydrazones and analogs as cholesterol lowering agents |
US7223791B2 (en) | 2001-06-26 | 2007-05-29 | Takeda Pharmaceutical Company Limited | Function regulator for retinoid relative receptor |
JP2003081832A (ja) * | 2001-06-26 | 2003-03-19 | Takeda Chem Ind Ltd | レチノイド関連受容体機能調節剤 |
WO2003062230A1 (en) * | 2002-01-21 | 2003-07-31 | Eisai Co., Ltd. | Conbinatorial library of heterocycle compounds |
US20060247216A1 (en) * | 2002-10-25 | 2006-11-02 | Haj-Yehia Abdullah I | Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments |
EP1578413A2 (en) * | 2002-11-29 | 2005-09-28 | Yissum Research Development Company of The Hebrew University of Jerusalem | Ace-inhibitors having antioxidant and no-donor activity |
EP2363129A1 (en) * | 2004-10-13 | 2011-09-07 | PTC Therapeutics, Inc. | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases |
WO2008064136A2 (en) * | 2006-11-17 | 2008-05-29 | Acadia Pharmaceuticals Inc. | Compounds with activity at retinoic acid receptors |
ES2882797T3 (es) * | 2009-04-02 | 2021-12-02 | Merck Serono Sa | Inhibidores de dihidroorotato deshidrogenasa |
CN103649079B (zh) | 2010-12-22 | 2016-11-16 | Abbvie公司 | 丙型肝炎抑制剂及其用途 |
US9630896B2 (en) | 2013-11-22 | 2017-04-25 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-H/halo/ether-phenol compounds |
JP6596090B2 (ja) * | 2014-12-17 | 2019-10-23 | キングス カレッジ ロンドン | レチノイン酸受容体ベータ(RARβ)アゴニストとしてのビシクロヘテロアリール−ヘテロアリール−安息香酸化合物 |
AU2016243702B2 (en) | 2015-03-31 | 2021-10-07 | Syros Pharmaceuticals, Inc. | Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists |
WO2016190871A1 (en) * | 2015-05-28 | 2016-12-01 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-h/halo/ether-phenol compounds |
BR112018070547A2 (pt) | 2016-04-08 | 2019-02-12 | Syros Pharmaceuticals, Inc. | agonistas de rara para o tratamento de aml e mds |
US9868994B2 (en) | 2016-04-08 | 2018-01-16 | Syros Pharmaceuticals, Inc. | Methods of stratifying patients for treatment with retinoic acid receptor-α agonists |
GB201610867D0 (en) * | 2016-06-22 | 2016-08-03 | King's College London | Crystalline forms of a therapeutic compound and processes for their preparation |
CN109942427B (zh) * | 2019-04-17 | 2022-02-18 | 云南农业大学 | 一种单萜酚类衍生物及其合成方法和在农药中的应用 |
JP2024516023A (ja) | 2021-05-04 | 2024-04-11 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 避妊薬の化合物及び方法 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3743656A (en) * | 1969-05-01 | 1973-07-03 | Wyeth John & Brother Ltd | Thiophene and furan lower alkanoic acids and derivatives |
DE2258276C3 (de) * | 1972-11-28 | 1981-08-13 | Bayer Ag, 5090 Leverkusen | Triazolyl-stilbene, sowie deren Herstellung und Verwendung als optische Aufheller |
CH187973A4 (de) * | 1973-02-09 | 1977-03-31 | Hoechst Ag | Verfahren zum optischen Aufhellen von Textilmaterialien |
US4129568A (en) * | 1977-05-12 | 1978-12-12 | Monsanto Company | 2-[3-Aryl-2-isoxazolin-5-yl]benzoates |
US4166732A (en) * | 1977-05-12 | 1979-09-04 | Monsanto Company | Oxadiazol-5-yl-benzoates |
US4135910A (en) * | 1977-05-12 | 1979-01-23 | Monsanto Company | Oxadiazol-3-yl-benzoates as plant growth regulants |
US4139366A (en) * | 1977-05-12 | 1979-02-13 | Monsanto Company | 2-[5-aryl-2-isoxazolin-3-yl]benzoates and use as herbicides |
SU1051083A1 (ru) * | 1981-09-18 | 1983-10-30 | Предприятие П/Я Р-6496 | 2-(2-Карбоксифенил)-5-арилоксазолы в качестве органических люминофоров сине-фиолетового свечени в органических растворител х и водной среде и способ их получени |
US5428052A (en) * | 1984-09-19 | 1995-06-27 | Centre Internationale De Recherches Dermatologiques (C.I.R.D.) | Aromatic heterocyclic derivatives and their therapeutic and cosmetic use |
LU85544A1 (fr) * | 1984-09-19 | 1986-04-03 | Cird | Derives heterocycliques aromatiques,leur procede de preparation et leur application dans les domaines therapeutique et cosmetique |
JP2752630B2 (ja) * | 1988-03-29 | 1998-05-18 | 大鵬薬品工業株式会社 | 新規安息香酸誘導体及びその製造方法 |
DE3903993A1 (de) * | 1989-02-10 | 1990-08-16 | Basf Ag | Diarylsubstituierte heterocyclische verbindungen, ihre herstellung und arzneimittel daraus |
US5162546A (en) * | 1989-09-19 | 1992-11-10 | Allergan, Inc. | Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity |
AU652189B2 (en) * | 1990-10-09 | 1994-08-18 | Allergan, Inc. | Chromans and thiochromans with retinoid-like activity |
JPH06502178A (ja) * | 1990-12-31 | 1994-03-10 | 藤沢薬品工業株式会社 | イミダゾトリアジン誘導体 |
KR0126300B1 (ko) * | 1992-12-28 | 1997-12-26 | 나이토 하루오 | 레티노이드 수용체(rar)에 결합하는 헤테로고리 탄산유도체 |
CA2153236A1 (en) * | 1993-01-11 | 1995-02-09 | Marcus F. Boehm | Compounds having selective activity for retinoid x receptors, and means for modulation of processes mediated by retinoid x receptors |
US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5624957A (en) * | 1995-06-06 | 1997-04-29 | Bristol-Myers Squibb Company | Rary-specific retinobenzoic acid derivatives |
EP0842923B1 (en) * | 1995-06-07 | 2006-03-01 | Nippon Shinyaku Company, Limited | Pyrrole derivatives and medicinal composition |
JP3964478B2 (ja) * | 1995-06-30 | 2007-08-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬 |
US5776699A (en) * | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
JPH0983725A (ja) | 1995-09-07 | 1997-03-28 | Sony Corp | 映像信号処理装置 |
JP2834697B2 (ja) | 1995-10-11 | 1998-12-09 | サンタニー株式会社 | ホームごたつ用脚 |
US5908858A (en) * | 1996-04-05 | 1999-06-01 | Sankyo Company, Limited | 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses |
US5776954A (en) * | 1996-10-30 | 1998-07-07 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
EP0946507B1 (en) * | 1996-12-10 | 2003-09-24 | G.D. SEARLE & CO. | Substituted pyrrolyl compounds for the treatment of inflammation |
US6077850A (en) * | 1997-04-21 | 2000-06-20 | G.D. Searle & Co. | Substituted benzopyran analogs for the treatment of inflammation |
-
1997
- 1997-03-18 JP JP53335197A patent/JP3995716B2/ja not_active Expired - Fee Related
- 1997-03-18 WO PCT/JP1997/000852 patent/WO1997034869A1/ja active IP Right Grant
- 1997-03-18 NZ NZ331466A patent/NZ331466A/en not_active IP Right Cessation
- 1997-03-18 HU HU9902645A patent/HUP9902645A3/hu unknown
- 1997-03-18 EP EP97907344A patent/EP0889032A4/en not_active Withdrawn
- 1997-03-18 AU AU19423/97A patent/AU723930B2/en not_active Ceased
- 1997-03-18 US US09/125,522 patent/US6121309A/en not_active Expired - Fee Related
- 1997-03-18 CN CNB2004100420998A patent/CN1255396C/zh not_active Expired - Fee Related
- 1997-03-18 KR KR10-1998-0707382A patent/KR100485642B1/ko not_active IP Right Cessation
- 1997-03-18 CA CA002247451A patent/CA2247451C/en not_active Expired - Fee Related
- 1997-03-18 CN CNB971931518A patent/CN1211361C/zh not_active Expired - Fee Related
-
1998
- 1998-09-17 NO NO19984331A patent/NO312759B1/no not_active IP Right Cessation
-
1999
- 1999-09-22 US US09/400,980 patent/US6110959A/en not_active Expired - Fee Related
-
2000
- 2000-07-21 US US09/621,889 patent/US6358995B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU1942397A (en) | 1997-10-10 |
CA2247451C (en) | 2006-01-03 |
KR20000064666A (ko) | 2000-11-06 |
KR100485642B1 (ko) | 2005-09-30 |
US6121309A (en) | 2000-09-19 |
HUP9902645A3 (en) | 1999-12-28 |
CN1214042A (zh) | 1999-04-14 |
NO984331L (no) | 1998-11-11 |
CA2247451A1 (en) | 1997-09-04 |
WO1997034869A1 (fr) | 1997-09-25 |
NZ331466A (en) | 2000-06-23 |
CN1548428A (zh) | 2004-11-24 |
CN1211361C (zh) | 2005-07-20 |
US6358995B1 (en) | 2002-03-19 |
AU723930B2 (en) | 2000-09-07 |
EP0889032A1 (en) | 1999-01-07 |
JP3995716B2 (ja) | 2007-10-24 |
NO984331D0 (no) | 1998-09-17 |
US6110959A (en) | 2000-08-29 |
CN1255396C (zh) | 2006-05-10 |
EP0889032A4 (en) | 2000-01-05 |
NO312759B1 (no) | 2002-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP9902645A2 (hu) | Kondenzált gyűrűt tartalmazó karbonsavszármazékok | |
BG101250A (en) | Salts of an anti-migraine indole derivative | |
NO2005024I2 (no) | Ester av 5-aminolevulinsyre som fotosensibiliseringsmiddel i fotokjemoterapi, anvendelse derav, samtfarmasoytisk blanding, produkt, utstyrsett og fre mgangsmaate for in vitro-diagnostisering | |
WO2004032848A3 (en) | Pgd2 receptor antagonists for the treatment of inflammatory diseases | |
LU91145I2 (fr) | FIROCOXIB facultativement sous forme d'un sel pharmaceutiquement acceptable (PREVICOX). | |
MXPA03004251A (es) | Derivados de benzodiazepina como moduladores del receptor gaba a. | |
HUP9902136A2 (hu) | Szubsztituált ciklusos aminosavszármazékok, alkalmazásuk, a vegyületeket tartalmazó gyógyászati készítmények | |
PE20000556A1 (es) | Preparaciones farmaceuticas estabilizadas de gabapentina y proceso para prepararla | |
DE69331190T2 (de) | Überbrückte azabicyclische derivate als substanz p antagonisten | |
NO962490L (no) | Orale formuleringer av S(+)-ibuprofen | |
DE69725978D1 (de) | Chalcon-derivate und medikamente die diese enthalten | |
AU2623095A (en) | Piperazine derivatives as 5ht1a antagonists | |
MA27412A1 (fr) | Nouveaux pyrimidine-4,6-dicarboxamides pour l'inhibition selective de collagenases | |
HUP0101112A2 (hu) | Piperidinil-aminometil-trifluor-metil-ciklikus-éter típusú vegyületek substance P antagonistaként történő felhasználása és ezeket tartalmazó gyógyszerkészítmények | |
BR0311593A (pt) | Derivados de 1-sulfonil-4-aminoalcoxi indol como moduladores de receptor 5-ht6 para tratamento dos distúrbios de snc | |
BG106293A (en) | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | |
BR9507231A (pt) | Uso de derivados de ácido carboxílico para a produção de drogas | |
RU95113434A (ru) | Диметилбензофураны и диметилбензопираны, их применение в качестве 5-нт*003-антагонистов, способы их получения, фармацевтическая композиция | |
RU94030470A (ru) | Производные 1-(арилалкиламиноалкил)имидазола, способ их получения, фармацевтическая композиция и способ лечения | |
DK0804418T3 (da) | Platelataggregationshæmmere | |
ES2039272T3 (es) | Sales opticamente activas a base de un tiazolidin-4-carboxilato sustituido y 3-cloro-2-hidroxipropiltrimetilamonio, su preparacion y empleo. | |
BR9812085A (pt) | "método para a sìntese de derivados de quinolina" | |
MXPA05011294A (es) | Compuestos de fosfonato anti-inflamatorios. | |
HUP9904638A2 (hu) | Szubsztituált benzopiránszármazékok alkalmazása gyógyszerkészítmények előállítására | |
ES8501763A1 (es) | "procedimiento para la fabricacion de derivados de la tetrahidro-5.6.7.7. 4h-tieno (3, 2-c) piridinona-2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB9A | Succession in title |
Owner name: EISAI R&D MANAGEMENT CO., LTD., JP Free format text: FORMER OWNER(S): EISAI CO., LTD., JP |
|
FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |